ProPhase Labs, Inc. (PRPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRPH POWR Grades
- Value is the dimension where PRPH ranks best; there it ranks ahead of 92.97% of US stocks.
- PRPH's strongest trending metric is Growth; it's been moving down over the last 177 days.
- PRPH ranks lowest in Momentum; there it ranks in the 13th percentile.
PRPH Stock Summary
- PRPH's current price/earnings ratio is 4.24, which is higher than only 7.87% of US stocks with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, PROPHASE LABS INC is reporting a growth rate of -1,035.63%; that's higher than only 1.72% of US stocks.
- As for revenue growth, note that PRPH's revenue has grown 273.85% over the past 12 months; that beats the revenue growth of 96.68% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to PROPHASE LABS INC, a group of peers worth examining would be ASRT, PIPR, WWE, BGCP, and BOXL.
- Visit PRPH's SEC page to see the company's official filings. To visit the company's web site, go to www.prophaselabs.com.
PRPH Valuation Summary
- PRPH's EV/EBIT ratio is 3.5; this is 64.65% lower than that of the median Healthcare stock.
- PRPH's price/sales ratio has moved down 1.5 over the prior 243 months.
Below are key valuation metrics over time for PRPH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PRPH | 2023-01-20 | 1.0 | 2.1 | 4.6 | 3.5 |
| PRPH | 2023-01-19 | 1.0 | 2.1 | 4.5 | 3.4 |
| PRPH | 2023-01-18 | 1.0 | 2.1 | 4.6 | 3.5 |
| PRPH | 2023-01-17 | 1.1 | 2.3 | 4.9 | 3.7 |
| PRPH | 2023-01-13 | 1.0 | 2.2 | 4.8 | 3.7 |
| PRPH | 2023-01-12 | 1.0 | 2.2 | 4.9 | 3.7 |
PRPH Growth Metrics
- The 4 year cash and equivalents growth rate now stands at -98.37%.
- Its 5 year cash and equivalents growth rate is now at -98.37%.
- Its 3 year revenue growth rate is now at 824.74%.
The table below shows PRPH's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 145.98 | 23.093 | 31.497 |
| 2022-06-30 | 131.252 | 14.939 | 26.551 |
| 2022-03-31 | 111.302 | 14.56 | 17.71 |
| 2021-12-31 | 79.042 | -13.619 | 6.273 |
| 2021-09-30 | 39.048 | -15.74 | -5.294 |
| 2021-06-30 | 33.416 | -10.699 | -1.724 |
PRPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PRPH has a Quality Grade of F, ranking ahead of 3.86% of graded US stocks.
- PRPH's asset turnover comes in at 0.618 -- ranking 52nd of 680 Pharmaceutical Products stocks.
- NBIX, CEMI, and ENDP are the stocks whose asset turnover ratios are most correlated with PRPH.
The table below shows PRPH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.618 | 0.488 | -0.022 |
| 2021-03-31 | 0.733 | 0.470 | 0.011 |
| 2020-12-31 | 0.738 | 0.317 | -0.105 |
| 2020-09-30 | 0.839 | 0.299 | -0.131 |
| 2020-06-30 | 0.876 | 0.309 | -0.152 |
| 2020-03-31 | 0.680 | 0.266 | -0.244 |
PRPH Price Target
For more insight on analysts targets of PRPH, see our PRPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.50 | Average Broker Recommendation | 1.75 (Moderate Buy) |
PRPH Stock Price Chart Interactive Chart >
PRPH Price/Volume Stats
| Current price | $8.08 | 52-week high | $15.25 |
| Prev. close | $8.21 | 52-week low | $6.20 |
| Day low | $7.92 | Volume | 65,000 |
| Day high | $8.23 | Avg. volume | 54,311 |
| 50-day MA | $9.83 | Dividend yield | N/A |
| 200-day MA | $10.39 | Market Cap | 131.53M |
ProPhase Labs, Inc. (PRPH) Company Bio
ProPhase Labs, Inc. manufactures zinc gluconate glycine lozenges and homeopathic gum. The Company's products reduce the duration and severity of common cold symptoms. ProPhase also manufactures nutrition and weight management products.
Latest PRPH News From Around the Web
Below are the latest news stories about PROPHASE LABS INC that investors may wish to consider to help them evaluate PRPH as an investment opportunity.
While insiders own 21% of ProPhase Labs, Inc. (NASDAQ:PRPH), individual investors are its largest shareholders with 60% ownershipIf you want to know who really controls ProPhase Labs, Inc. ( NASDAQ:PRPH ), then you'll have to look at the makeup of... |
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening TestGARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it has completed its previously announced acquisition of the world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets from Stella Diagnostics, Inc. (“Stella”). The BE-Smart test is focused on the early detection of esophageal cance |
ProPhase Labs''s Return On Capital Employed OverviewPulled from Benzinga Pro data, ProPhase Labs (NASDAQ: PRPH ) posted Q3 earnings of $968 thousand, an increase from Q2 of 87.0%. Sales dropped to $24.20 million, a 16.82% decrease between quarters. ProPhase Labs earned $7.45 million, and sales totaled $29.09 million in Q2. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com |
ProPhase Labs Stock: Betting On The DNA Sequencing Market For Future Growth (NASDAQ:PRPH)ProPhase Labs has strengthened its fundamentals through profitable COVID-19 testing. Read why I downgrade my initial stance to a Hold position for PRPH stock. |
ProPhase Labs Acquires Rights to Novel Esophageal Cancer TestGARDEN CITY, NY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. “ProPhase” (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics… |
PRPH Price Returns
| 1-mo | -15.22% |
| 3-mo | -29.06% |
| 6-mo | -24.27% |
| 1-year | 11.91% |
| 3-year | 325.26% |
| 5-year | 239.50% |
| YTD | -16.10% |
| 2022 | 34.31% |
| 2021 | -21.90% |
| 2020 | 365.99% |
| 2019 | -37.46% |
| 2018 | 45.16% |
Continue Researching PRPH
Here are a few links from around the web to help you further your research on ProPhase Labs Inc's stock as an investment opportunity:ProPhase Labs Inc (PRPH) Stock Price | Nasdaq
ProPhase Labs Inc (PRPH) Stock Quote, History and News - Yahoo Finance
ProPhase Labs Inc (PRPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...